To our knowledge, there have been no randomized controlled trials (RCT) to determine if colonoscopy surveillance intervals can be safely extended in elevated risk CRC surveillance cohorts based on prior low FIT Hb concentration. Here, GSTM1 is linked to colorectal carcinoma.